Firefly Bio

Executive Summary

Firefly Bio is a private biotechnology company based in San Francisco, California, pioneering the development of Degrader Antibody Conjugates (DACs) for cancer therapy. Founded in 2020, the company leverages its proprietary Degronimid platform to combine the targeted protein degradation capabilities of small molecules with the specificity of antibody-drug conjugates (ADCs). By delivering protein degraders directly to cancer cells via antibodies, Firefly aims to overcome limitations of traditional ADCs, such as payload toxicity and resistance, and unlock new therapeutic opportunities. The platform has the potential to expand the druggable proteome and address previously undruggable targets, positioning Firefly at the forefront of next-generation ADC innovation. As a preclinical-stage company, Firefly Bio has not yet disclosed specific pipeline candidates or financing details. However, its unique approach and focus on DACs have generated interest in the biotech community. The company's success hinges on advancing its lead programs toward the clinic and securing strategic partnerships or funding to support development. With a strong scientific foundation and a differentiated technology, Firefly Bio is well-positioned to contribute to the evolving landscape of targeted cancer therapies. Key upcoming milestones include the selection of lead candidates, IND-enabling studies, and potential early clinical data, which will be critical in validating the Degronimid platform and driving its value proposition.

Upcoming Catalysts (preview)

• Q3 2026Lead DAC Program IND Filing30% success
• Q2 2026Series A/B Financing Announcement70% success
• Q2 2026Preclinical Data Presentation at Major Conference (e.g., AACR)80% success